Login to Your Account

Nightstarx closes $35M series B round, sets sights on choroideremia trial

By Cormac Sheridan
Staff Writer

Monday, November 9, 2015

DUBLIN – UK gene therapy firm Nightstarx Ltd. took in $35 million in a series B round to move its lead program in choroideremia into a pivotal trial next year and to move two other programs in inherited retinal diseases into the clinic by 2017.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription